

Kim A Margolin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4908279/publications.pdf>

Version: 2024-02-01

197
papers

21,895
citations

19608

61
h-index

9073

144
g-index

206
all docs

206
docs citations

206
times ranked

22673
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999, 17, 2105-2105.	0.8	1,810
2	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	0.8	1,809
3	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
4	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.	3.8	1,111
5	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
6	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 459-465.	5.1	995
7	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
8	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	0.8	914
9	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	0.8	746
10	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	5.1	711
11	Cytokines in Cancer Immunotherapy. <i>Cancers</i> , 2011, 3, 3856-3893.	1.7	549
12	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3743-3748.	0.8	381
13	Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data. <i>Journal of Clinical Oncology</i> , 2001, 19, 851-856.	0.8	365
14	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020, 183, 347-362.e24.	13.5	349
15	Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 247-256.	0.8	326
16	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3133-3140.	0.8	307
17	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	0.8	274
18	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4906-4911.	0.8	267

#	ARTICLE	IF	CITATIONS
19	Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 618-630.	2.3	249
20	CCI-779 in metastatic melanoma. Cancer, 2005, 104, 1045-1048.	2.0	245
21	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. Journal of Molecular Diagnostics, 2014, 16, 56-67.	1.2	234
22	Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. Journal of Clinical Oncology, 2011, 29, 2178-2184.	0.8	226
23	Updates in the management of brain metastases. Neuro-Oncology, 2016, 18, 1043-1065.	0.6	209
24	Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. Journal of Urology, 2007, 178, 1883-1887.	0.2	186
25	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 2017, 86, 37-45.	1.3	183
26	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 2013, 10, 588-598.	12.5	177
27	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
28	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 5552-5561.	3.2	150
29	Transferred melanoma-specific CD8 ⁺ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4592-4597.	3.3	142
30	A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer. Clinical Genitourinary Cancer, 2006, 5, 57-60.	0.9	140
31	Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. Journal of Cancer Research and Clinical Oncology, 2002, 128, 214-218.	1.2	134
32	The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 561-568.	3.2	133
33	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 1692-1704.	5.1	129
34	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncology, The, 2013, 14, e396-e406.	5.1	116
35	Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2*Positive Advanced Melanoma. Journal of Clinical Oncology, 2008, 26, 2292-2298.	0.8	103
36	A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer, 2017, 123, 2688-2697.	2.0	103

#	ARTICLE	IF	CITATIONS
37	Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 672-693.	2.3	103
38	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 627-642.	1.5	102
39	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network Cancer Research Group (E4697). Journal of Clinical Oncology, 2015, 33, 4066-4076.	0.8	101
40	Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. Nature Communications, 2018, 9, 4297.	5.8	101
41	T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. Journal of Clinical Oncology, 2016, 34, 3787-3795.	0.8	98
42	Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group. Blood, 1997, 90, 3844-3852.	0.6	93
43	Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemotherapy and Pharmacology, 2000, 46, 19-26.	1.1	93
44	Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy. Blood, 1999, 93, 2798-2806.	0.6	90
45	Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 960-977.	2.3	90
46	Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides. Journal of Immunotherapy, 2007, 30, 762-772.	1.2	89
47	The treatment of brain metastases from malignant melanoma. Seminars in Oncology, 2002, 29, 518-524.	0.8	88
48	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e20-e32.	5.1	87
49	Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438). Clinical Cancer Research, 2012, 18, 1129-1137.	3.2	86
50	Tumor-Infiltrating Lymphocytes in Melanoma. Current Oncology Reports, 2012, 14, 468-474.	1.8	82
51	Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer, 2015, 121, 432-440.	2.0	80
52	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. Journal of Experimental Medicine, 2016, 213, 1133-1139.	4.2	78
53	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. Cancer, 2008, 113, 2139-2145.	2.0	77
54	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clinical Cancer Research, 2011, 17, 6574-6581.	3.2	77

#	ARTICLE	IF	CITATIONS
55	Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512. PLoS ONE, 2012, 7, e48787.	1.1	77
56	A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2004, 54, 331-42.	1.1	76
57	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG—ACRIN Cancer Research Group (E2804). Journal of Clinical Oncology, 2015, 33, 2384-2391.	0.8	75
58	Dolastatin-10 in metastatic melanoma: a phase II and pharmacokinetic trial of the California Cancer Consortium. Investigational New Drugs, 2001, 19, 335-340.	1.2	74
59	Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel. Clinical Cancer Research, 2004, 10, 461-467.	3.2	73
60	Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 502-535.	2.3	71
61	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology, 2021, 23, 1961-1973.	0.6	66
62	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
63	Prognostic Indicators and Survival in Patients With Stage IIIB Inflammatory Breast Carcinoma After Dose-Intense Chemotherapy. Journal of Clinical Oncology, 2004, 22, 1839-1848.	0.8	60
64	Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2163-2169.	0.8	59
65	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
66	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	0.6	59
67	Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma. Journal of Immunotherapy, 1994, 15, 147-153.	1.2	58
68	Kidney Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 175-182.	2.3	56
69	A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Investigational New Drugs, 2012, 30, 741-748.	1.2	52
70	Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2000, 1, 46-54.	2.1	49
71	Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Investigational New Drugs, 1995, 13, 157-162.	1.2	48
72	NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-29.	2.3	48

#	ARTICLE	IF	CITATIONS
73	High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994, 73, 1678-1685.	2.0	47
74	Cellular immunotherapy and autologous transplantation for hematologic malignancy. <i>Immunological Reviews</i> , 1997, 157, 231-240.	2.8	44
75	Phase I Trial of BAY 50-4798, an Interleukin-2 Specific Agonist in Advanced Melanoma and Renal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3312-3319.	3.2	44
76	A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 18-24.	1.0	43
77	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part II: Management of IL-2 Toxicity and Studies with Other Cytokines. <i>Medical Oncology</i> , 2001, 18, 209-220.	1.2	40
78	Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 778-785.	2.0	40
79	Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. <i>Investigational New Drugs</i> , 2005, 23, 235-239.	1.2	39
80	Ipilimumab in a Phase II trial of melanoma patients with brain metastases. <i>Oncolmmunology</i> , 2012, 1, 1197-1199.	2.1	39
81	Hepatic metastasis in granulosa cell tumor of the ovary. <i>Cancer</i> , 1985, 56, 691-695.	2.0	38
82	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 293-298.	1.1	38
83	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	3.4	38
84	Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, 103-106.	1.2	36
85	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 48.	1.3	36
86	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 527-541.	1.5	36
87	Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. <i>Clinical Cancer Research</i> , 2007, 13, 1232-1237.	3.2	35
88	High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994, 73, 125-134.	2.0	34
89	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	3.2	34
90	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , 2006, 106, 2624-2629.	2.0	33

#	ARTICLE	IF	CITATIONS
91	Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy. <i>Seminars in Oncology</i> , 2010, 37, 468-472.	0.8	33
92	An open-label, phase 2 trial of RPL4610 (angiozyme) in the treatment of metastatic breast cancer. <i>Cancer</i> , 2012, 118, 4098-4104.	2.0	33
93	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 458-469.	1.5	31
94	Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. <i>Cancer</i> , 2014, 120, 1617-1619.	2.0	30
95	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	2.0	29
96	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part I. IL-2-Based Clinical Trials. <i>Medical Oncology</i> , 2001, 18, 197-208.	1.2	27
97	Cytokine therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1495-1505.	1.4	27
98	Inhibition of vascular endothelial growth factor in the treatment of solid tumors. <i>Current Oncology Reports</i> , 2002, 4, 20-28.	1.8	26
99	Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 903-911.	2.0	26
100	Management of Metastatic Melanoma in 2018. <i>JAMA Oncology</i> , 2018, 4, 857.	3.4	26
101	Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. <i>ESMO Open</i> , 2021, 6, 100252.	2.0	26
102	Multidisciplinary Approach to Brain Metastasis from Melanoma; Local Therapies for Central Nervous System Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 399-403.	1.8	26
103	A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2013, 36, 490-495.	1.2	25
104	Biochemotherapy for melanoma. <i>Cancer</i> , 2004, 101, 435-438.	2.0	24
105	Cytokine Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 261-274.	0.9	24
106	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 393-398.	1.8	24
107	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 393-398.	1.8	22
108	Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 36-45.	2.0	20

#	ARTICLE	IF	CITATIONS
109	Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated Patients with Advanced Ovarian Cancer: Long-Term Follow-up. <i>Gynecologic Oncology</i> , 2000, 77, 433-438.	0.6	20
110	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 181-191.	1.4	20
111	Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain. <i>Seminars in Oncology</i> , 2015, 42, 459-465.	0.8	20
112	A Phase II Study of the Continuous Intravenous Infusion of Interleukin-6 for Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 1995, 18, 52-56.	1.2	19
113	Methodologic guidelines for the design of high-dose chemotherapy regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 414-432.	2.0	19
114	Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery. <i>Journal of Clinical Oncology</i> , 2010, 28, 1196-1202.	0.8	19
115	Multidisciplinary Approach to Brain Metastasis from Melanoma; Local Therapies for Central Nervous System Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 399-403.	1.8	18
116	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor- α positive breast cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	17
117	Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 2177-2178.	13.9	15
118	NCI 8628: A randomized phase 2 study of ziv- α flibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018, 124, 4332-4341.	2.0	15
119	State of the science 60th anniversary review. <i>Cancer</i> , 2008, 113, 1728-1743.	2.0	14
120	Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 927-933.	1.1	14
121	Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. Relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. <i>Journal of Clinical Laboratory Analysis</i> , 2003, 17, 184-194.	0.9	13
122	Oblimersen and α -interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 705-711.	1.2	13
123	Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. <i>JAAD Case Reports</i> , 2020, 6, 195-197.	0.4	13
124	The unique association of malignant histiocytosis and a primary gonadal germ cell tumor. <i>Medical and Pediatric Oncology</i> , 1992, 20, 162-164.	1.0	12
125	Phase II trial of biochemotherapy with interferon α , dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 292-296.	1.2	12
126	High Dose Chemotherapy and Stem Cell Support in the Treatment of Germ Cell Cancer. <i>Journal of Urology</i> , 2003, 169, 1229-1233.	0.2	11

#	ARTICLE	IF	CITATIONS
127	Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1149-1155.	1.1	11
128	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 120-131.	2.3	11
129	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1483.	1.3	10
130	High-risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. <i>Cancer</i> , 1993, 71, 2351-2357.	2.0	9
131	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 327-332.	1.1	9
132	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 353-359.	1.1	9
133	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 283-289.	1.1	9
134	Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. <i>Current Oncology Reports</i> , 2009, 11, 405-411.	1.8	9
135	Summary of the primer on tumor immunology and the biological therapy of cancer. <i>Journal of Translational Medicine</i> , 2009, 7, 11.	1.8	9
136	A phase II trial of gefitinib and pegylated IFN α in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011, 16, 494-9.	1.0	9
137	29th Annual meeting of the Society for Immunotherapy of Cancer (SITC). , 2015, 3, .		9
138	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 641-650.	1.8	9
139	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.	2.3	9
140	High titer, High thermal amplitude Cold Autoagglutinin Not Associated with Hemolytic Anemia. <i>Vox Sanguinis</i> , 1988, 55, 26-29.	0.7	8
141	Phase II Trial of Intraperitoneal Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with Advanced Ovarian Cancer—Long-Term Follow-Up. <i>Gynecologic Oncology</i> , 1999, 75, 419-426.	0.6	8
142	A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 403-410.	1.1	8
143	Introduction to the Role of the Immune System in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 537-558.	0.9	8
144	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>Journal of NeuroInterventional Surgery</i> , 2015, 7, e34-e34.	2.0	8

#	ARTICLE	IF	CITATIONS
145	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e59-e69.	1.8	8
146	Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling. Annals of Surgical Oncology, 2020, 27, 5240-5247.	0.7	8
147	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 641-650.	1.8	8
148	Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96h for the treatment of advanced malignancies. Cancer Chemotherapy and Pharmacology, 2004, 54, 241-248.	1.1	7
149	Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. Community Oncology, 2008, 5, 367-374.	0.2	7
150	Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Tumor: Clinical Outcome and Quality of Life in Long-Term Survivors. Clinical Genitourinary Cancer, 2013, 11, 121-127.	0.9	7
151	Treatment of metastatic malignant melanoma with trimetrexate: A phase II study. Medical and Pediatric Oncology, 1990, 18, 49-52.	1.0	6
152	Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biology of Blood and Marrow Transplantation, 2001, 7, 284-293.	2.0	6
153	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study. Journal of Immunotherapy, 2007, 30, 839-846.	1.2	6
154	BRAF inhibition and beyond in advanced melanoma. Lancet, The, 2012, 380, 320-322.	6.3	5
155	Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report. Molecular and Clinical Oncology, 2021, 14, 46.	0.4	5
156	Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US. Journal of Community and Supportive Oncology, 2015, 13, 131-138.	0.1	5
157	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. Blood, 2004, 104, 810-810.	0.6	5
158	Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. Cancer Chemotherapy and Pharmacology, 1994, 35, 161-164.	1.1	4
159	An Introduction to Foundation and Industry-Sponsored Research: Practical and Ethical Considerations. Hematology American Society of Hematology Education Program, 2007, 2007, 498-503.	0.9	4
160	A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemotherapy and Pharmacology, 2007, 59, 549-557.	1.1	4
161	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. Expert Review of Dermatology, 2013, 8, 479-487.	0.3	4
162	Melanoma's deadly march to the brain. Cancer, 2011, 117, 1560-1563.	2.0	3

#	ARTICLE	IF	CITATIONS
163	Ipilimumab in patients with melanoma and brain metastases – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e277-e278.	5.1	3
164	Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110422.	0.2	3
165	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 293-298.	1.1	3
166	Autologous and allogeneic high-dose therapy for melanoma. <i>Current Oncology Reports</i> , 2001, 3, 338-343.	1.8	2
167	Treatment of Advanced Melanoma with Immunological Checkpoint Block. <i>Current Oncology Reports</i> , 2011, 13, 430-432.	1.8	2
168	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014011362-bcr2014011362.	0.2	2
169	Brain Metastases in Melanoma: Moving Toward Curing the Incurable. <i>Journal of Oncology Practice</i> , 2016, 12, 545-546.	2.5	2
170	Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!. <i>Cancer</i> , 2016, 122, 3263-3266.	2.0	2
171	What is new on the horizon in melanoma brain metastasis?. <i>ESMO Open</i> , 2019, 4, e000579.	2.0	2
172	Tumor-infiltrating lymphocytes are associated with improved survival in node-positive Merkel cell carcinoma: A national cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	2
173	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	1.7	2
174	Management of Advanced Germ Cell Cancer in Patients With Unfavorable Prognosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 77-83.	2.3	1
175	Shortening the Infusion Time of Anticancer Drugs: Who Will Benefit?. <i>Journal of Clinical Oncology</i> , 2007, 25, 2642-2643.	0.8	1
176	Indoor Tanning Use Among U.S. Youth – Can Skin Health Behaviors be Legislated?. <i>Current Oncology Reports</i> , 2010, 12, 290-291.	1.8	1
177	Adoptive T-Cell Therapy of Melanoma Using Designer T-Cell Receptors. <i>Current Oncology Reports</i> , 2011, 13, 427-429.	1.8	1
178	Cytokines in the Treatment of Cancer. , 2013, , 173-210.		1
179	Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-2.	0.2	1
180	Metabolic Checkpoint of Immune Cells in Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019, 9, 581-583.	7.7	1

#	ARTICLE	IF	CITATIONS
181	Interleukin-2 and Cancer Therapy. , 2007, , 307-316.		1
182	Mitotic rate and younger age as predictors of sentinel lymph node positivity. Current Oncology Reports, 2005, 7, 375, 376.	1.8	1
183	Immunotherapy of Colorectal Cancer. BioDrugs, 1994, 2, 42-52.	0.7	0
184	IL-2 in the therapy of melanoma and other malignancies. Medical Oncology, 2009, 26, 23-31.	1.2	0
185	CCR9:CCL25 in melanoma metastatic to small intestine. Current Oncology Reports, 2009, 11, 331-332.	1.8	0
186	Control of experimental melanoma by host CXCR2. Current Oncology Reports, 2009, 11, 333-334.	1.8	0
187	Indoor Tanning and Substance-Related Disorderâ€™Related Behaviors With Similar Treatment?. Current Oncology Reports, 2010, 12, 288-289.	1.8	0
188	Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade. JAMA Oncology, 2016, 2, 1186.	3.4	0
189	After a treatment breakthroughâ€™progress, plateaus, and raising the bar. Cancer, 2017, 123, 2087-2088.	2.0	0
190	Reply to A. Shinde et al. Journal of Clinical Oncology, 2019, 37, 1031-1032.	0.8	0
191	And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 386-397.	1.8	0
192	Melanoma and Other Cutaneous Malignancies. , 2008, , 2037-2059.		0
193	Targeting the mTOR, PI3K, and AKT Pathways in Melanoma. , 2012, , 107-123.		0
194	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2019, , 1-34.		0
195	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2020, , 1421-1454.		0
196	Mac Cheever (1944â€™2021): a tribute to a life of achievement and service. , 2022, 10, e004433.		0
197	Molecular staging in stage II and III melanoma patients. Current Oncology Reports, 2005, 7, 376.	1.8	0